← #nieuws

Alnylam opent nieuw kantoor in Amsterdam

Komst toonaangevend RNAi biotechbedrijf bevestigt ontwikkeling life sciences hub in Nederland.

Alnylam Pharmaceuticals, het toonaangevende biotechbedrijf uit de Verenigde Staten, dat zich richt op RNAi-therapie, een zeer vernieuwende categorie geneesmiddelen, opende vandaag een nieuw kantoor in Amsterdam. Deze beslissing komt voort uit het vertrouwen in de combinatie van talent, infrastructuur, het R&D-ecosysteem en het zeer hoge niveau van de academische ziekenhuizen in Amsterdam en Nederland. Daarnaast speelt de open en innovatieve cultuur in Nederland een belangrijke rol.

Nederland neemt een steeds belangrijkere positie in ten aanzien van Alnylam’s activiteiten in Europa. Dit zorg voor grote investeringen in operationele en financiële activiteiten en in de supply chain, inclusief samenwerkingsverbanden met lokale bedrijven. Ook blijft Nederland de basis voor de uitvoering van verschillende ‘Fase 3’ klinische testen met betrekking tot de door Alnylam ontwikkelde medicijnen.

De opening van het nieuwe kantoor werd gevierd met een evenement, dat samen met verschillende partners is georganiseerd: amsterdam inbusiness, Health~Holland en het Invest in Holland Network. Phillip A. Sharp (Nobelprijswinnaar en Institute Professor aan het ‘Koch Institute for Integrative Cancer Research’ van het MIT) gaf de keynote speech. Daarnaast waren er bijdrages van Wouter Bos (CEO van Invest NL), Hans Schikan (Pharm.D en waarnemend boegbeeld van de Topsector Life Sciences & Health) en Jaap Groothoff (hoogleraar aan de Faculteit der Geneeskunde van de Universiteit van Amsterdam).

Nederland is een van de meest compacte en innovatieve life sciences ecosystemen van de wereld, met meer dan 2900 bedrijven in de life sciences sector en de gezondheidszorg (verantwoordelijk voor 34.000 banen) binnen een straal van 200 kilometer. Naast de grote hoeveelheid aan bedrijven en banen, is Nederland ook wereldleider op het gebied van octrooiaanvragen voor medische technologieën. Verder wordt het innovatieve vermogen van Nederland gedreven door gezondheids- en onderzoeksinstituten van wereldklasse, zoals de twaalf universiteiten, 85 ziekenhuizen (waarvan zeven universitair medisch centra) en meer dan 200 publiek-private samenwerkingsverbanden tussen onderzoeksorganisaties, bedrijven en overheden. Ook op het gebied van digitale zorg is Nederland een absolute wereldleider, zo is het de nummer 1 op het gebied van het toepassen van eHealth-oplossingen in ziekenhuizen en klinieken.

Barry Greene, President, Alnylam Pharmaceuticals: “Wij zijn zeer enthousiast over onze groeiende aanwezigheid in Nederland, met onze wetenschappelijke, operationele en commerciële activiteiten. We zien Nederland als onze toekomstige hub voor Europese activiteiten. Dit is te danken aan het innovatieve ecosysteem voor biotechnologie en het aantrekkelijke vestigingsklimaat, waardoor bedrijven met baanbrekende innovaties zich in Nederland ontwikkelen. Wij zijn onze partners amsterdam inbusiness, Health~Holland, Invest in Holland en natuurlijk de gemeente Amsterdam, erg dankbaar voor hun steun en het enthousiasme waarmee wij hier zijn ontvangen.”

Wouter Bos, bestuursvoorzitter van Invest NL: “De keuze van Alnylam Pharmaceuticals om hun nieuwe kantoor in Amsterdam te vestigen is heel logisch. Wij delen de focus op onderzoek van de hoogste kwaliteit: de Nederlandse universiteiten zijn van zeer hoog niveau – ze behoren tot de beste 2% van de wereld. Amsterdam, waar de VU en de UvA zijn gevestigd, heeft de grootste studentenpopulatie van Nederland. Tijdens mijn vorige functie als voorzitter van het VU Medisch Centrum, nu Amsterdam AMC, hadden wij grote waardering voor de samenwerking tussen Alnylam en onze professoren. Ik verwacht dat onze gezamenlijke focus op de wetenschap en uitzonderlijk onderzoek zal bijdragen aan het succes van Alnylam in Nederland.’’

Udo Kock, locoburgemeester van Amsterdam: “De aanwezigheid van Alnylam in Amsterdam onderstreept de kracht en aantrekkelijkheid van de Amsterdamse life sciences en gezondheidssector. Samen met ons hoogstaande wetenschappelijke onderwijs en onderzoek, uitgevoerd in de academische ziekenhuizen, gespecialiseerde onderzoeksinstituten en natuurlijk met de aanstaande verhuizing van het Europees Geneesmiddelenbureau (EMA), werken we allemaal samen om de gezondheid van mensen te verbeteren. Met onze partnersteden in Nederland verwelkomen we bedrijven die innovatie in de life sciences en gezondheidssector stimuleren en die willen bijdragen aan dit belangrijke doel. ”

Hans Schikan, Pharm.D, waarnemend boegbeeld van de Topsector Life Sciences & Health: “Nederland is nu al een toonaangevende life sciences hub, die de potentie heeft om bij de top van de wereld te horen. Goed onderzoek, sterk ondernemerschap, een regering die meedenkt en betrokken burgers die graag samenwerken vormen de basis voor succes. We heten Alnylam dan ook van harte welkom in Nederland.”

Bron: Anylam

← #nieuws

ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals

ProQR receives exclusive worldwide license for IONIS-RHO-2.5Rx, now QR-1123, for autosomal dominant retinitis pigmentosa (adRP), a rare inherited form of blindness with no approved therapy. A first in human Phase 1/2 clinical trial in adRP patients is expected to start in 2019.

ProQR Therapeutics a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the signing of an agreement with Ionis Pharmaceuticals to license QR-1123 (formerly “IONIS-RHO-2.5Rx”), an RNA medicine for autosomal dominant retinitis pigmentosa (adRP) caused by the P23H mutation in the rhodopsin (RHO) gene.

“Building on the recent proof of concept with QR-110 in LCA10 patients, we have confidence in the potential of single stranded RNA-targeted therapies to treat patients with genetic eye diseases,” said Daniel A. de Boer, chief executive officer of ProQR. “By acquiring the rights to QR-1123, we have strategically expanded our pipeline in retinal diseases. Ionis has a wealth of experience in discovery and development of antisense drugs and we look forward to working with them on this important program. Unlike other molecules we are developing, QR-1123 is a gapmer with a mutant allele-specific knockdown mechanism of action. If validated, it would further broaden the potential of RNA-targeted therapies in retinal diseases. We are excited to start clinical development to explore QR-1123’s potential in helping patients with P23H adRP.”

Under the terms of the agreement, ProQR was granted an exclusive worldwide license to QR-1123 and relevant patents. ProQR made an upfront payment in ordinary shares in the aggregate amount of $2.5 million, at $22.23 per share, which represents a 20% premium (based on the volume weighted average price of the previous 20 trading days) to its common stock, to Ionis upon signing the agreement. ProQR will also make future milestone payments, certain of which will be made in equity and others in cash or equity at ProQR’s discretion, and royalties on net sales of 20% through the royalty term.

Preclinical activities have been completed by Ionis and were presented at the 2015 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) and published in a peer-reviewed article, Murray et al 2015, IOVS. A natural history study in patients with P23H adRP has been conducted. The results of this study provide valuable information on disease progression in these patients, which is important data for designing the clinical development plan. ProQR expects to start a Phase 1/2 clinical trial in patients with adRP in 2019, pending submission and clearance of the IND application by the U.S. Food and Drug Administration (FDA).

Brett P. Monia, Ph.D., chief operating officer and senior vice president of translational medicine at Ionis, added, “IONIS-RHO-2.5Rx, now QR-1123, is an antisense oligonucleotide we designed to specifically target only the mRNA from the disease-causing rhodopsin gene, which has a single nucleotide P23H mutation, while preserving expression of the mRNA from the normal rhodopsin gene, which is important for the eye to function properly.  IONIS-RHO-2.5Rx was developed by Ionis scientists dedicated to discovering innovative therapeutics to fight diseases where no other treatments have proven effective or even existed. We believe that ProQR has the ophthalmology expertise and experience in developing oligonucleotide drugs for the eye to rapidly bring this program through clinical development and ultimately to patients.”

Source ProQR

← #nieuws

Brightlands Agrifood Ventures grows to € 20 mln in a second closing

Brightlands Agrifood Ventures has realized a second closing of its fund with three additional funding parties, each with a commitment of € 1 million. The three parties are LLTB (Limburgse Land- en Tuinbouwbond), Van Herk Ventures and an undisclosed private individual active in modern greenhouse farming. The additional commitments bring the total size of the fund to slightly more than € 20 million. The parties involved signed for this second closing on 25 October, at the Brightlands Campus Greenport Venlo.

Fund manager Kim de Boer comments: “We are happy to welcome these additional investors to the fund. Each of these parties have a strong added value to help build startups and enhance the Brightlands ecosystem in the agrifood domain”.

Brightlands Agrifood Ventures was launched in October 2017 and is a venture fund managed by Chemelot Ventures Management. Through its funds Chemelot Ventures Management provides funding to startups and fast-growing companies in and around the Brightlands campuses in the south of the Netherlands. With this fund they include agrifood in their focus. The fund will invest in approximately ten promising technology startups in agrifood that have a close link with the Brightlands Campus Greenport Venlo. The fund focuses on innovations in crop protection and optimization, seed improvement, precision agriculture, valorization of agricultural and horticultural waste and healthy nutrition.

The first closing of Brightlands Agrifood Ventures stood at a total of € 17 million, funded by Rabobank Venlo (€ 5 million), the Province of Limburg (€ 5 million) and LIOF (€ 1 million) while the fund’s management also contributed. Moreover, the Rijksdienst voor Ondernemend Nederland (RVO) pledged an amount of € 6 million under the so-called Seed Capital scheme.

Leon Faassen, chairman of LLTB: “The current position of agriculture as one of the major economical strengths in Limburg (and the Netherlands) is the result of good entrepreneurship combined with on-going innovation. LLTB wants to contribute to the further development of agriculture in Limburg and help enable innovations and support startups”.

Dharminder Chahal, Van Herk Ventures: “Van Herk Ventures is committed to investing in Green Tech as it offers solutions to a major world issue by developing innovative solutions for safer food production under changing climate conditions. The Brightlands Campus Greenport Venlo is an inspiring initiative and we are happy to support it.”

LLTB (Limburgse Land- en Tuinbouwbond) is the institution which represents the interests of farmers and covers all agricultural sectors: agriculture, greenhouse farming, horticulture, cattle breeding, horse keeping, arboriculture, nature maintenance and development as well as multifunctional agriculture.

Van Herk Ventures, located in Rotterdam is a well-established venture capital investor with an impressive and longstanding track record. Van Herk Ventures is active both via direct investments and via fund of fund investments.

Chemelot Ventures Management is an independent regional venture capital fund manager in the south of the Netherlands (Limburg). Apart from Brightlands Agrifood Ventures it manages two other venture capital funds: Limburg Ventures, a € 15 million fund founded in 2004 and Chemelot Ventures, a € 40 million fund founded in 2014. Chemelot Ventures is funded by DSM, LIOF, Rabobank and the Province of Limburg and has invested in 14 startups to date. Its focus is on sustainability (Brightlands Chemelot Campus) and health (Brightlands Health Campus Maastricht).

Source: Chemelot Ventures

← #nieuws

Galapagos and AbbVie restructure CF collaboration

,

Galapagos and AbbVie announce a restructuring of their cystic fibrosis (CF) alliance; AbbVie takes over all programs in CF and continues the development of a triple combination therapy for CF.

AbbVie will obtain exclusive worldwide rights to the current CF investigational drug candidate portfolio developed by the two companies in the course of the collaboration. The portfolio includes all potentiator and corrector candidates. AbbVie will be responsible for all future activities and will bear all costs associated with this portfolio in CF going forward.

Galapagos will receive an upfront payment of $45 million from AbbVie. Galapagos will be eligible to receive up to $200 million in additional milestone payments from AbbVie pending completion of certain development, regulatory, and commercial achievements in CF by AbbVie. In the event AbbVie receives regulatory approval and realizes commercial sales in CF, Galapagos is further eligible to receive royalties ranging from single digit to low teens. AbbVie further agrees to pay Galapagos tiered single digit royalties of global commercial sales, if approved, from these candidates achieved in indications outside of CF.

Galapagos retains exclusive global commercial rights to develop GLPG2737, a candidate C2 corrector, in all indications outside of CF. AbbVie is eligible for future milestone payments and tiered single digit royalties on future global commercial sales, if approved, in indications outside CF.

“We are very pleased with the outcome of our discussions with AbbVie regarding the future of the CF portfolio. We believe that AbbVie is well-equipped to further develop this CF portfolio and to come up with a competitive triple combination product for CF patients,” said Onno van de Stolpe, CEO of Galapagos. “Galapagos’ strength is new mode of action programs. Our pipeline is robust, and we will continue to focus our resources on these innovative programs.”

Source: Galapagos

← #nieuws

Join the Dutch Life Sciences conference

,

HollandBIO is proud to be a partner of the 14th edition of the Dutch Life Sciences conference that will be hosted by Leiden Bio Science Park and take place at the CORPUS Congress Centre on November 29, 2018. The conference inspires and promote an open exchange of information including trends and developments in the industry.

´The next wave of innovation for patients´

The programme consists of plenary and parallel sessions, an investors forum, active networking possibilities and an information market. In addition the winner of the Venture Challenge will be announced.

A very inspiring and dynamic programme, with TOP speakers like Eline Vrijland-van Beest (Founder and CEO NightBalance), Michel de Baar (Executive Director, BD&L Europe at MSD), Sander van Deventer (CSO and General Manager Amsterdam at UniQure), Ton Logtenberg (President and CEO Merus) and Ronald Plasterk (CSO myTomorrows), stimulates discussions and facilitates interactions between business executives, R&D specialists, policy makers and investors from the (inter)national life sciences sector.

The developments in the following fields will be addressed in various parallel sessions; – Industry 4.0 in life sciences – microbiome therapeutics – oncology – digital healthcare – regenerative medicines and – next generation platform technologies in drug discovery and validation

Check out the complete line up and topics!

HollandBIO members are eligable for a 10% discount. More information

#dls #November29 @Corpus #lbsp #lifesciences

← #nieuws

10 jaar Innovatiekrediet: innovaties met impact

,

Veelbelovende en uitdagende innovaties met een uitstekend marktperspectief, die ondernemers niet helemaal zelf kunnen financieren: daarvoor kan het Innovatiekrediet uitkomst bieden. Ter gelegenheid van het 10 jarig bestaan licht RVO een paar mooie voorbeelden uit. Neem een kijkje op de website en laat je inspireren!

← #nieuws

Genmab Announces Net Sales DARZALEX® (daratumumab)

Genmab announced that worldwide net sales of DARZALEX (daratumumab), as reported by Johnson & Johnson, were USD 498 million in the third quarter of 2018 compared to USD 317 million in the third quarter of 2017, an increase of 57%. The 2018 third quarter net sales were USD 318 million in the U.S. and USD 180 million in the rest of the world.

Johnson & Johnson reported worldwide operational growth (excluding the impact of foreign currency movements) between the two third quarter periods of 60%.The growth was partially offset by a one-time adjustment outside the U.S. related to accruals for retroactive pricing adjustments which negatively impacted this worldwide operational growth by 16 percentage points.

Genmab will receive royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen Biotech, Inc. to develop, manufacture and commercialize DARZALEX.

Source: Genmab

← #nieuws

Vestigingsklimaat krijgt nieuwe impuls door handhaven dividendbelasting

Vorig jaar werd in het Regeerakkoord een pakket aan maatregelen aangekondigd om het Nederlandse vestigingsklimaat te versterken. Een goed vestigingsklimaat is voor Nederland van groot belang en geldt als een randvoorwaarde voor een ijzersterk innovatieklimaat. Afgelopen week maakte premier Rutte bekend af te zien van de meest veelbesproken maatregel: de afschaffing van de dividendbelasting. Deze week presenteerde staatssecretaris Snel van Financiën de alternatieve plannen. Het gaat onder andere om een verdere verlaging van de vennootschapsbelasting, een overgangsregeling voor het verkorten van de looptijd van de 30% regeling en een verhoging van de tweede schijf van de WBSO van 14% naar 16%. De maatregelen zijn een mooie impuls voor het innovatieve MKB en verstevigen de positie van Nederland als aantrekkelijk vestigingsland. Lees hier de hele kamerbrief met de aangekondigde maatregelen.

← #nieuws

Intravacc and TherapyX partner to develop the world’s first prophylactic vaccine against Gonorrhea

,

Intravacc and TherapyX are pleased to announce that they have entered into a strategic partnership for the co-development of NGoXIMTM, the world’s first prophylactic vaccine against infection with Neisseria gonorrhoeae. This new vaccine is intended to enhance specific adaptive immune responses that provide lasting, protective immunity against N. gonorrhoeae. NGoXIMTM is a combination of a sustained-release formulation of interleukin 12 (GneX12TM) and bacterial outer membrane vesicles (OMV) formulated for mucosal delivery.

No effective gonorrhea vaccine is currently available and the disease is known to be acquired repeatedly with apparently no development of protective immunity from previous infection. The American Centers for Disease Control and Prevention (CDC) has listed antibiotic-resistant N. gonorrhoeae as one of the top three pathogens presenting “an immediate public health threat that requires urgent and aggressive action.” A recent WHO technical consultation on vaccines against sexually transmitted infections (2017) called for renewed efforts to develop a vaccine against gonorrhea. This partnership effort is a direct response to that call.

Under the terms of the partnership agreement, TherapyX will focus efforts on IND-enabling efficacy and toxicology studies in primates while Intravacc will be responsible for the discovery and development of OMVs with improved immunogenic properties and reduced toxicity. Financial terms were not disclosed.

“We are thrilled to partner with Intravacc” said Dr. Dominick L. Auci, Vice President for Research and Development at TherapyX. “They bring over 100 years of expertise in vaccines including novel OMV technology to this important project. We couldn’t be working with a more experienced, innovative and dedicated team”.

“We are delighted to be working with TherapyX” said Mr. Nico Oudendijk, General Director of Intravacc. “The IL-12 technology they bring into the project is key to develop an efficacious vaccine against this disease.”

Source: Intravacc

← #nieuws

European biotech funding on track for record year

The European biotech sector is on track to break its annual funding record, according to BioWorld. After a big third quarter, the total for the first nine months of the year stands at $6.3 billion, putting the region on course to clear the $8 billion bar.

European biotechs made a solid start to 2018, pulling in $3.9 billion over the first six months. But the fundraising haul really took off in the third quarter, when major follow-on offerings contributed to the sector pulling in $2.5 billion. The surge means the sector is set to ease past last year’s total of $6.9 billion and puts it a solid quarter away from breaking the $8 billion barrier.

The deals underpinning the sector’s move toward the new fundraising high says something about the state of biotech in the region today. Galapagos, a European biotech with the once-rare aspiration of becoming a midsized, standalone company, led the way with a $346 million follow-on offering that built on positive clinical trial data.

Argenx and ProQR Therapeutics made similar moves to Galapagos, pulling in $301 million and $104 million, respectively, after generating data on clinical-phase candidates.

The financing highlights the emergence of a clutch of growing European biotechs with aspirations to take drugs deep into the clinic. However, they also show the importance of the U.S. in the fulfillment of these aspirations. Galapagos, Argenx and ProQR are all listed on Nasdaq.

Yet, while Nasdaq is the default option for European biotechs, Idorsia is showing there is another way. Idorsia, which spun out of Actelion following the Johnson & Johnson takeover, used its listing on the Swiss stock exchange to raise $307 million to fund a slate of late-phase trials.

While the follow-on market thrived in the third quarter, the IPO pipeline dried up. The VC world was more active. As previously reported, British biotechs, led by Nasdaq-bound gene therapy player Orchard Therapeutics, raised serious sums of money in the third quarter. Orchard was one of six U.K. companies in the list of top 10 private European financings for the quarter.

The question now is whether European biotechs can maintain the momentum built up in the third quarter and hit a new funding high. Early signs are good. GW Pharmaceuticals got the quarter underway with a $300 million follow-on offering, moving the total for the year above $6.6 billion.

Source: FierceBiotech